AOD-9604: selected references HeartPep literature library, reviewed 2026-11-09 https://heartpep.com/us/research/library/aod-9604 1. Heffernan M, Summers RJ, Thorburn A, et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice Endocrinology. DOI: https://doi.org/10.1210/endo.142.12.8522 PMID: 11713213 Source: https://pubmed.ncbi.nlm.nih.gov/11713213/ Verification: Abstract / bibliographic record. 2. Stier H, Vos E, Kenley D (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans Journal of Endocrinology and Metabolism. DOI: https://doi.org/10.4021/jem157w Source: https://www.jofem.org/index.php/jofem/article/view/157/194 Verification: Abstract / bibliographic record. 3. U.S. Food and Drug Administration (2024). FDA evaluation of AOD-9604-related bulk drug substances Pharmacy Compounding Advisory Committee briefing document. Source: https://www.fda.gov/media/183584/download Verification: Full text. These are selected background references, not evidence that a HeartPep product or batch matches a studied preparation. Cite and assess the original papers.